3-5 years of experience
Concerned about your lack of experience? Learn More...
Employment Type:
Full time
Job Category:
See more jobs for students and recent grads who studied:
Manager, Medical Publications, SMA
Biogen | Cambridge, Massachusetts
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company

Job Description

External Posting TitleManager, Medical Publications, SMA
Job DescriptionThe Manager, Medical Publications leads the development and execution of strategic publication plans in support of the multiple sclerosis therapeutic area. The Manager works directly with the respective Product Scientific Communications Lead, Medical Communication Manager, Program Medical Directors and liaises with other key functions in Biogen (e.g. Global Research and Development, Global Market Access) in the development of the publication plan and also works closely with external medical communications agencies, alliance partners and external authors to develop publications (congress abstracts, posters, manuscripts, etc.).
As part of responsibilities for publications development, this person ensures compliance with Biogen publications policy and standard operating procedures and with external guidelines on good publication practices. Additionally, the Manager updates internal stakeholders on product publication-related activities.
The Manager will also participate in internal and cross-functional team meetings to assure alignment of publications with the medical strategy and communication objectives.
Some of the major responsibilities of this role include:
1. Developing strategic publication plan

• Coordinates meetings and leads discussions of cross-functional Core Publication Plan Team and/or Joint Publication Team with an alliance partner to develop a publication plan which is aligned with the Medical Strategy and communication objectives; the publication plan is revised annually

• Works with agency to develop initial draft publication strategy, and coordinates review and approval of the strategic publication plan and tactics

2. Coordinating the development of publications (journal articles, abstracts, and medical meeting presentations) reporting scientific and clinical data

• Leads Core Publication Plan Team meetings and/or Joint Publication Team Meetings with alliance partner

• Reviews draft abstracts, posters, slides, and manuscripts critically for content

• Leads and coordinates meetings to discuss conflicting comments on manuscripts

• Follows-up with agency regarding the status of manuscripts in development

• Ensures development of publications complies with Biogen publication policy

• Manages publications budget

• Aligns resources to support the development of all publications in the plan with Associate Director, Medical Publications

3. Managing medical communications agency

• Oversees agency maintenance of documents in publication planning software, Datavision; responsible for consistency, accuracy, and currency of documentation in Datavision

• Regularly monitors Datavision and documents compliance with publications policy

4. Providing regular updates on publication activities related to product

• Maintains bibliographies

• Participates in monthly Therapeutic Literature Alert meetings and completes associated deliverables

• Reports monthly publication metrics on key objectives
LocationCambridge, MA, US
Job CategoryGlobal Medical/Medical Affairs
Requisition Number31672BR
• 3+ years of related experience at pharmaceutical or biotechnology company or medical communications agency.

• Successful track record of implementation of global publication programs

• Knowledge and understanding of the pharmaceutical commercialization process

• Development of global medical plans and global medical communication and publication strategy

• Management of consultants and vendors

• Excellent verbal & written communication skills

• Ability to work in ambiguity and/or time-sensitive matters
• Master's, PharmD, PhD or MD in a biological science or related field strongly preferred
About BiogenCorporate Overview

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.

One of the pioneers in biotechnology, Biogen was founded in 1978 and today serves patients in nearly 90 countries. Our global headquarters and R&D operations are located in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland, world-class manufacturing facilities in Research Triangle Park, North Carolina, USA and Hillerod, Denmark, and affiliate locations around the world.

Our Science

We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.

For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer's disease, Parkinson's disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.

Biogen is revolutionizing biologics manufacturing, developing the industry's most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.

Our Corporate Citizenship

The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek's 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science's list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work.

All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.

Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.

About Biogen

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)

This company profile was created by AfterCollege and is about Biogen. This page is not endorsed by or affiliated with Biogen. For questions regarding company profiles, please email: care@aftercollege.com.